Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Drugs for Immunotherapy Market Size Forecast: How Big Could The Market Get By 2030?
The drugs for immunotherapy market has witnessed rapid expansion in recent years. It is forecast to grow from $310.48 billion in 2025 to $349.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.6%. The market’s historical growth can be ascribed to several factors, including the initial limited immunotherapy options, the dependence on conventional cancer treatments, a rising prevalence of cancer and autoimmune diseases, an increase in clinical trials for monoclonal antibodies, and enhancements in healthcare infrastructure.
The market for immunotherapy drugs is anticipated to experience substantial expansion in the coming years. Its valuation is projected to reach $570 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.0%. This projected growth during the forecast period is due to advancements in bispecific and conjugated antibodies, the broadening scope of personalized immunotherapy, increased uptake of checkpoint inhibitors, greater investments in therapeutic vaccine research, and the incorporation of digital patient monitoring and AI-guided immunotherapy. Key developments expected in this period encompass the growing use of monoclonal antibodies and checkpoint inhibitors, expansion in treatments for cancer immunotherapy and autoimmune diseases, heightened creation of therapeutic and preventive vaccines, the extension of t-cell receptor and cytokine-based therapies, and the incorporation of immunotherapy into both ambulatory and hospital settings.
Get A Free Sample Report With In-Depth Market Insights:
Drugs for Immunotherapy Market Industry Drivers: What’s Behind The Revenue Growth?
The expanding healthcare expenditure is projected to stimulate the growth of the drugs for immunotherapy market in the future. Healthcare expenditure refers to the total monetary amount spent on healthcare goods and services within a specific region or country over a defined period, encompassing costs for doctor visits, hospital stays, surgeries, diagnostic procedures, and treatments. Such financial resources for health care are allocated by individuals, healthcare providers, insurance companies, and government agencies to cover the expenses linked with drugs for immunotherapy and various treatments. For instance, in December 2024, the Centers for Medicare & Medicaid Services, a US-based agency administering Medicare and Medicaid programs, stated that U.S. health care expenditures in 2023 saw an increase of 7.5%, reaching $4.9 trillion, which amounts to roughly $14,570 for each individual. Thus, the rising healthcare expenditure is a key factor propelling the expansion of the drugs for immunotherapy market.
Drugs for Immunotherapy Market Segment Trends And Revenue Contributors
The drugs for immunotherapy market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types
2) By Therapy Area: Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas
3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Interferons: Interferon Alfa, Interferon Beta, Interferon Gamma
3) By Interleukins: Interleukin-2 (IL-2), Interleukin-6 (IL-6), Interleukin-12 (IL-12)
4) By Vaccines: Preventive Vaccines, Therapeutic Vaccines
5) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
6) By Other Types: Cancer Cell Therapies, Cytokine Therapy, T-Cell Receptor Therapy
#Drugs for Immunotherapy Market Growth Trends: What’s Shaping The Future Outlook?
Major companies operating in the drugs for immunotherapy market are concentrating on developing novel products, such as Keytruda (pembrolizumab), to offer dependable services to customers. Keytruda (pembrolizumab) is an immunotherapy, specifically a targeted therapy drug classified as an immune checkpoint inhibitor for adult patients. For instance, in January 2023, Merck & Co., Inc., a US-based pharmaceutical company, introduced Keytruda (pembrolizumab), which received approval from the Food and Drug Administration, a US-based federal agency. Keytruda (pembrolizumab) immunotherapy is utilized to address various types of cancer by collaborating with the immune system to combat cancer cells. KEYTRUDA (pembrolizumab) is also approved as an adjuvant treatment for non-small cell lung cancer (NSCLC). This represents a notable progression in the field of cancer treatment and is projected to have a favorable effect on the healthcare industry.
Drugs for Immunotherapy Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the drugs for immunotherapy market are F. Hoffmann-La Roche Ltd., Novartis AG, Merck & Co. Inc., UbiVac, Bayer AG, Celgene Corporation, Incyte Corporation, Juno Therapeutics Inc., Bluebird bio, Celldex Therapeutics, BeiGene, BioNTech AG, CytomX Therapeutics, Eisai Co. Ltd., Flexus Biosciences Inc., Genscript Biotech Corporation, Harpoon Therapeutics Inc., Heptares Therapeutics Ltd., Ignyta Inc., Immatics Biotechnologies, Jounce Therapeutics Inc.
View The Full Drugs for Immunotherapy Market Report:
Drugs for Immunotherapy Market Geographic Spread And Regional Opportunities
North America was the largest region in the immunotherapy market in 2025. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in the drugs for immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
